Last reviewed · How we verify
Ceredase (ALGLUCERASE)
Ceredase (ALGLUCERASE) is a hydrolytic lysosomal glucocerebroside-specific enzyme used to treat chronic non-neuropathic Gaucher's disease. It was originally developed and is currently owned by Genzyme. This small molecule modality was FDA-approved in 1991 for its approved indications. The commercial status of Ceredase is not explicitly stated, but it is likely patented. Key safety considerations include the potential for hypersensitivity reactions and the need for careful monitoring of patients.
At a glance
| Generic name | ALGLUCERASE |
|---|---|
| Sponsor | Sanofi |
| Drug class | Hydrolytic Lysosomal Glucocerebroside-specific Enzyme |
| Modality | Enzyme |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 1991 |
Approved indications
- Chronic non-neuropathic Gaucher's disease
Common side effects
Key clinical trials
- Genetic Studies of Lysosomal Storage Disorders
- Blood-Brain-Barrier Disruption With Cerezyme in Patient's With Parkinson's Disease (NA)
- Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL) (PHASE1,PHASE2)
- Positron Emission Tomography (PET) Imaging in People With Gaucher Mutations
- MR-guided Focused Ultrasound Plus GCase (NA)
- Safety and Efficacy of Eliglustat With or Without Imiglucerase in Pediatric Patients With Gaucher Disease (GD) Type 1 and Type 3 (PHASE3)
- International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry
- Genotypic Influences on Network Progression in Parkinson's Disease
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ceredase CI brief — competitive landscape report
- Ceredase updates RSS · CI watch RSS
- Sanofi portfolio CI